Pharmaceutical company Johnson & Johnson on Thursday applied to the Food and Drug Administration for Emergency Use Authorization (EUA) for their one-dose COVID-19 vaccine. Within hours after Johnson & Johnson’s application, the FDA announced that their advisory board will vote February 26 on whether to grant the EUA, which would allow the immediate distribution of the vaccine to the public. Johnson & Johnson released their Phase 3 trial information January 29, declaring the single-shot vaccination was “72% effective in the US and 66% effective overall at preventing moderate to severe COVID-19” and “85% effective overall in preventing severe disease” 28 days after inoculation. Unlike the Moderna and Pfizer-BioNTech vaccines currently being distributed nationwide, the Johnson & Johnson vaccine only requires one shot to be effective, and can be stored at conventional refrigeration temperatures for a much longer time.
Johnson & Johnson applies for FDA authorization for one-dose COVID-19 vaccine
